RO 6864018

Drug Profile

RO 6864018

Alternative Names: RO-6864018

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 11 Nov 2016 Adverse events, pharmacodynamic and pharmacokinetics data from a phase I trial in Hepatitis B presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 01 Feb 2015 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in New Zealand (PO) (NCT02391805)
  • 01 Nov 2014 Roche completes a phase I trial in Healthy volunteers in Singapore (NCT02015715)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top